Premium
Aberrant NK cell associated marker ( CD 56 and CD 57) expression in chronic lymphocytic leukemia
Author(s) -
Dorwal Pranav,
Mehra Simmi,
Pande Amit,
Jain Dharmendra,
Smeeta G.,
Sachdev Ritesh,
Raina Vimarsh
Publication year - 2015
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21254
Subject(s) - chronic lymphocytic leukemia , cd5 , cd23 , lymphoproliferative disorders , phenotype , immunophenotyping , cd20 , flow cytometry , cd38 , leukemia , medicine , immunology , pathology , biology , cancer research , lymphoma , gene , antibody , immunoglobulin e , stem cell , genetics , cd34
Background Chronic lymphocytic leukemia (CLL) is one of the commonest leukemias that has been reported extensively throughout the literature. The characteristic phenotype includes co‐expression of CD5 and CD23, along with dim expression of light chain and CD22/CD79b, with lack of FMC7. The immunophenotypic scoring system given by Matutes has been used to differentiate CLL from non‐CLL chronic lymphoproliferative disorders. Various aberrancies have been described in CLL cases, including abnormal (dim or bright) expression of B cell markers and lineage infidel T cell, myelomonocytic, or rarely Natural killer (NK) cells markers. However, the aberrant co‐expression of CD56 and CD57 has not yet been reported. Method and Results We hereby report a case of 62‐year female with a typical CLL phenotype and Matutes score of 5, showing the expression of CD56 and CD57. Conclusion This entity may represent a rare subtype of CLL which needs to be studied more extensively for its prognostic implications. This is the first report of CLL with aberrant CD56 and CD57 expression. © 2015 International Clinical Cytometry Society